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Abstract
Objective: Methadone coverage is poor in many countries due in part to methadone induction being possible only in
specialized care (SC). This multicenter pragmatic trial compared the effectiveness of methadone treatment between two
induction models: primary care (PC) and SC.
Methods: In this study, registered at ClinicalTrials.Gov (NCT00657397), opioid-dependent individuals not on methadone
treatment for at least one month or receiving buprenorphine but needing to switch were randomly assigned to start
methadone in PC (N= 155) or in SC (N = 66) in 10 sites in France. Visits were scheduled at months M0, M3, M6 and M12. The
primary outcome was self-reported abstinence from street-opioids at 12 months (M12) (with an underlying 15% non-
inferiority hypothesis for PC). Secondary outcomes were abstinence during follow-up, engagement in treatment (i.e.
completing the induction period), retention and satisfaction with the explanations provided by the physician. Primary
analysis used intention to treat (ITT). Mixed models and the log-rank test were used to assess the arm effect (PC vs. SC) on
the course of abstinence and retention, respectively.
Results: In the ITT analysis (n = 155 in PC, 66 in SC), which compared the proportions of street-opioid abstinent participants,
85/155 (55%) and 22/66 (33%) of the participants were classified as street-opioid abstinent at M12 in PC and SC,
respectively. This ITT analysis showed the non-inferiority of PC (21.5 [7.7; 35.3]). Engagement in treatment and satisfaction
with the explanations provided by the physician were significantly higher in PC than SC. Retention in methadone and
abstinence during follow-up were comparable in both arms (p = 0.47, p = 0.39, respectively).
Conclusions: Under appropriate conditions, methadone induction in primary care is feasible and acceptable to both
physicians and patients. It is as effective as induction in specialized care in reducing street-opioid use and ensuring
engagement and retention in treatment for opioid dependence.
Trial registration: Number Eudract 2008-001338-28; ClinicalTrials.gov: NCT00657397; International Standard Randomized
Controlled Trial Number Register ISRCTN31125511
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Introduction
Methadone is included in the WHO list of essential medicines
thanks to its effectiveness in treating opioid dependence, prevent-
ing HIV [1] and improving adherence to antiretroviral treatment
in HIV-infected individuals [2]. Despite this, access to methadone
remains limited because of the risk of overdose during induction,
especially in countries where the need for methadone is even
greater.
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While access to buprenorphine in primary care has been
possible since 1996 thanks to its safety profile [3,4], methadone
induction in France, as in most countries, is currently possible only
in specialized centers caring for substance dependence (located in
ad hoc sites or in hospitals) (hereafter specialized care or SC). In
France these centers can refer patients to PC only after the end of
methadone induction, i.e. when methadone doses are stabilized
(after at least 14 days).
The specific model of care for regulating methadone induction
can greatly influence its safety as the risk of overdose during the
induction phase remains a major concern. Internationally, the
regulations governing the extent to which methadone induction
(i.e. until dosage stabilization) is authorized in primary care (PC)
differ considerably. For example, methadone induction in PC is
legal in the UK, in Switzerland and in Canada under different
models of care. In contrast, France, the United States but also
other countries have no such system currently in place.
This means that in the many geographic areas underserved by
SC, opioid-dependent individuals seeking treatment have no
access to methadone. To tackle this situation, one of the objectives
of the French public health authorities’ national strategic plan for
prevention and care of Hepatitis was to consider using primary
care as an entry point for methadone treatment, based on the
results of a pragmatic trial. The trial, entitled Methaville, was
designed both to evaluate the feasibility of methadone induction in
PC and to compare outcomes in participants randomized into PC
induction with those randomized into SC induction. Being a
pragmatic trial, the objectives were to verify the feasibility and
acceptability of the PC induction model to physicians and patients,
and also to show that the main patient outcome (street-opioid
abstinence after one year of treatment) and secondary outcomes
(abstinence during follow-up, engagement in treatment, retention
in treatment and satisfaction with the explanations provided by the
physician) were all comparable between both induction arms.
Methods
The protocol for this trial and supporting CONSORT checklist
are available as Checklist S1 and English protocol S1.
Ethics
The Methaville ANRS trial is registered with the French
Agency of Pharmaceutical Products (AFSSAPS) under the number
2008-A0277-48, the European Union Drug Regulating Author-
ities Clinical Trials: Number Eudract 2008-001338-28, the
ClinicalTrials.gov Identifier: NCT00657397 and the International
Standard Randomized Controlled Trial Number Register
ISRCTN31125511. The study protocol was approved by the
Ethics Committee of Persons Protection in Paris, France. All
individuals provided written, informed consent before participat-
ing in the study.
Physicians and Participants
In this multicenter, pragmatic, randomized trial, for each study
site we selected an SC physician and nearby PC physicians who
already had field experience in care for opioid dependence and/or
training in care for drug dependence, and who were willing to
participate. Only PC physicians with patients potentially eligible
for enrollment in the study were selected because if methadone
induction in PC is officially adopted in France in the future, only
PC physicians meeting the above criteria will be targeted by
authorities as methadone prescribers. Ten sites in four geographic
areas (North, North-Eastern, South-Western and South-Eastern
France) were included, with each site having at least one SC and
one PC physician. These four geographical areas were chosen to
better target the different types of populations who would benefit
from access to methadone in primary care, as each geographical
area is characterized by different drug markets and drug user
practices/needs. Physicians (in PC and SC) enrolled opioid-
dependent individuals who were randomized to start methadone
either in PC or in SC.
Inclusion criteria were chosen to target a population represen-
tative of drug users needing/seeking methadone treatment in
France as follows: aged over 18 years old, seeking care for opioid
dependence and not prescribed methadone for at least one month
or receiving buprenorphine but needing to switch to methadone
for medical reasons (side effects, treatment misuse, etc.). Non-
inclusion criteria were similar to those in other studies involving
methadone prescription in PC [5,6] as follows: could not be
reached by phone for an interview and screening positive for
opioids/benzodiazepines/alcohol triple co-dependence, as assess-
ed by the MINI [7] (as this condition exposed participants to a
high risk of overdose [8,9]) and finally, for women, being pregnant.
Study design
The first visit took place when a patient seeking care for opioid
dependence or needing to switch treatment from buprenorphine
to methadone went to see a PC or SC physician participating in
the trial. After providing consent to participate the patient was
randomized into the PC or SC arm by this physician. To make
patient randomization feasible, each site had one SC with at least
one PC physician in the nearby vicinity. All PC and SC physicians
involved underwent a one-day training course both to standardize
methadone induction practices according to trial guidelines and to
acquaint them with trial procedures [10]. Trial guidelines
stipulated that the starting dose should be on average 30 mg
and not exceed 40 mg, with 10 mg increases every 2–4 days
thereafter until dose stabilization. This is comparable to metha-
done induction protocols used in other trials [5,11].
The ‘‘intervention’’ provided by trained physicians consisted in
at least fourteen-day supervised methadone induction either in PC
or in SC according to trial guidelines (Table 1). Thereafter,
supervision was required only for patients who were deemed to be
at risk of overdose. One main difference between both arms in the
model of care was that delays in initiating treatment were more
common in SC (see Table 1).
Participants were also followed up over one year through
medical visits and phone interviews at months 0 (M0, enrolment),
at 3, 6 and 12 months (M3, M6 and M12, respectively).
To emulate current care practices in France, patients could
choose to change arm after the induction phase, i.e. SC physicians
could refer their patient to a PC colleague who would prescribe
methadone and vice versa. Accordingly, arm changes (PC to SC or
SC to PC) were not considered as deviations from the protocol.
Further details and the pre-trial phase of the protocol are
described elsewhere [10].
Data sources and outcomes
The following 5 sources provided study data: a pre-enrollment
medical questionnaire, a medical questionnaire at each scheduled
visit (enrolment (M0), months 3, 6 and 12, respectively M3, M6
and M12), a short self-administered questionnaire (completed
during scheduled visits), a Computer Assisted Telephone Interview
(CATI) (conducted just after each scheduled visit) lasting no more
than 30 minutes, and when available, urine rapid tests [10].
Abstinence from street-opioids at M12 was chosen as the
primary outcome. Abstinence during the course of treatment,
engagement in treatment, retention in methadone maintenance
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treatment and patient satisfaction with the explanations provided
by the physician were secondary outcomes. The primary outcome,
abstinence from street opioids during the previous month, was
measured using a validated question [12], administered during
phone interviews by trained non-judgmental staff. This question
was also answered in the medical interviews at enrolment, M3, M6
and M12.
Methadone dose was defined as the number of mg/day of
methadone prescribed by the physician for each patient at each
medical visit.
Engagement in treatment was computed in those randomized to
each specific arm as the proportion of patients who actually started
methadone and remained in the trial until the stabilization of
dosages (i.e. until the end of induction). Follow-up participation
rates, i.e. participants who continued participating in study
interviews until M12, were computed for each arm.
Retention in methadone maintenance treatment was defined,
only for patients who actually started methadone treatment, as the
time between the first day of methadone induction and the last
known date that the patient was still receiving treatment. For
individuals still on methadone at M12, retention was set at 12
months.
A 5-point Likert scale measured patient satisfaction with the
explanations provided by his/her prescribing physician during
CATI at M6 only. This outcome was then dichotomized (very
satisfied vs. other).
There were three main reasons to justify the choice to use
patient self-reported street-opioid use as the primary outcome.
The first reason was to avoid introducing measures which would
not reflect routine practices in the field of care for drug
dependence in France (for example neither urine tests nor hair
analysis are routinely performed). These alternative measures
would have been negatively affected by several missing values.
Furthermore, any cases with complete values would most likely
have been biased, as urine testing is currently performed at the
discretion of the physician if he/she is doubtful about patients’
drug use. The second one was to place the patient at the center of
the study and consider his/her self-reported experience with
treatment (satisfaction with the explanations provided by the
physician) as a major outcome. This choice reflects the work in
other trials involving drug users and in other fields of medicine
where patient’s reported outcomes are considered as main
outcome measures [13,14]. Third, patient self-reports are valid
as PC physicians rely on them in clinical practice [15].
We chose the endpoint at M12 for the trial phase on the basis
that any comparison between arms would not be significant
enough immediately after the induction phase or indeed at M3,
and that any possible benefit could be confirmed after one year of
treatment.
The outcomes used in this pragmatic trial were those typically
used in trials assessing the efficacy of a treatment for opioid
dependence [5,6]. The only difference here is that they were used
to assess methadone effectiveness (and not efficacy) by induction
arm.
Safety issues
To ensure safety during induction, we implemented a wide
range of strategies minimizing overdose risk in the trial’s model of
care, including a one-day training session for PC physicians, strict
supervision of participants when they took their doses at the
pharmacy during treatment initiation, and fostering strong
collaboration between all the health professionals involved in the
study, including pharmacists (shared-care model) [16]. The non-
inclusion of patients with triple co-dependence (alcohol-opioid-
benzodiazepine) [8,9] does not constitute a restrictive criterion and
reflects standard practice for safety concerns. Methadone initiation
in these patients is possible only after benzodiazepine detoxifica-
tion.
Pharmacists and physicians involved in the trial had to signal
overdoses, signs of intoxication and lost-to-follow-up patients to
the center of methodology and management (CMM) (ORS
PACA- INSERM-IRD UMR912). The latter was required to
notify any severe adverse event, such as an overdose, to the French
Table 1. Features of the PC and SC model of care for methadone treatment (ANRS Methaville trial).
Methaville model for Primary Care (PC) Current Methadone model for specialized care (SC)
N During induction, methadone intake is delivered and supervised
daily at the pharmacy (with take home doses only for the
weekend).
Supervision is compulsory during induction.
N During induction, methadone is delivered daily at the center by the physician, the pharmacist or
the nurse or is delivered at the pharmacy (with take home doses only for the weekend).
Supervision is compulsory during induction.
N Psychosocial and health status assessment is not a necessary
condition to start methadone – referral to specialized center
if needed.
N It is recommended that Methadone induction is started after initial visits/interviews carried out
by different members of health staff:
a) A social counselor and/or a psychologist to obtain a psychosocial assessment of the patient;
b) A physician or a nurse to obtain an assessment of the general health of the patient;
c) An assessment of his/her social rights (health insurance, accommodation, resources, and
previous access to care for drug dependence).
N Referral to psychosocial counseling in SC during methadone
treatment if needed.
N Psychosocial counseling provided during methadone treatment.
N Methadone prescription possible the same day as the first
medical visit.
N Time before methadone prescription may be delayed by some days after the first medical visit,
depending on patient’s conditions (withdrawal syndromes, pregnancy, etc.).
N Doses are prescribed according to Methaville guidelines. N Doses are prescribed according to Methaville guidelines.
N Doses are reassessed at every medical visit (i.e. every 2–3 days)
during induction.
N Doses are reassessed at every medical visit (i.e. every 2–3 days) during induction.
N Urine analyses at first dose prescription and monitoring
once/twice a week during induction.
N Urine analyses at first dose prescription and monitoring once/twice a week during induction.
doi:10.1371/journal.pone.0112328.t001
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National Agency for Research on Aids and Viral Hepatitis
(ANRS) which in turn notified the French Agency of Pharmaceu-
tical Products (ANSM).
A list of 50 health-related symptoms included in the question-
naire helped document self-reported symptoms during follow-up.
Statistical considerations
Sample size. Although retention in treatment is the most
important outcome in patients receiving treatment for opioid
dependence [17] and even more important in the context of
decision-making by public health authorities, this trial was funded
for HCV prevention purposes with opioid abstinence being
considered the most pertinent primary outcome. It was therefore
designed with an underlying hypothesis of non-inferiority in terms
of the proportion of PC-inducted patients who were abstinent
from street-opioids at 12 months (M12) of methadone treatment
with respect to their SC counterparts.
The study hypothesis was that after one year of treatment, the
proportion of patients abstinent from street-opioids would be 70%
[18,19] for SC. Selecting an inferiority margin of 15 for patients
starting methadone in PC entailed recruiting a minimum of 150
patients in order to show the non-inferiority, if any, of the PC arm
for the primary outcome.
The choice of this margin reflected our willingness to accept
decreased effectiveness in PC in return for increased attractiveness
and engagement in PC treatment.
Randomization and masking. Randomization of patients
was performed centrally by the study’s methodology and data
management center (ORS PACA- INSERM-IRD UMR912), via
a secured intranet site, by simple random sampling with no block
control on randomization rate. Information about patient
randomization was confidentially stored and hidden from the
study research team - except statisticians and the data manager -
until the end of the last M12 interview, in December 2011. A
randomization ratio 2:1 (PC: SC) was chosen to deliberately over-
represent patients followed-up in PC to increase the probability of
detecting possible intoxications in PC during induction.
Statistical analysis. Medians and interquartile ranges (IQR)
and proportions were used to describe the distributions of
continuous and categorical variables, respectively. Distributions
of variables among the two groups were compared using Mann-
Whitney U test for continuous variables, Chi-Squared or Fisher
exact test for categorical variables.
The primary analysis used intention-to-treat (ITT) (n = 221) and
the primary outcome was measured using a validated question
[12] about opioid use during the previous month collected by
CATI or medical interview (when CATI data was incomplete).
The difference between both arms in the proportion of patients
reporting abstinence from street-opioids during the previous
month at M12 and the related 95% confidence interval (95%
CI) were computed. In this ITT analysis all patients who
discontinued follow-up before M12 for any reason (i.e. refused
to start methadone after randomization or discontinued follow-up
for any reason including treatment interruption, lost to follow-up,
incarceration etc.) were classified as ‘‘failure’’ i.e. street-opioid
users (see Fig. 1).
A ‘‘per protocol’’ analysis was also conducted only on individuals
still followed-up at month 12 (n = 162).
Participants still followed up at M12 but with missing values for
OTI (Opiate Treatment Index) at M12 were also classified as
street-opioid users in both the ITT and per protocol analysis. The
ITT classification for those who discontinued follow-up for any
reason and for those with missing data is particularly pertinent in
this population of opioid-dependent individuals because discon-
tinuation is generally associated with relapse into street-opioid use.
Logistic mixed models assessed the effects of time on methadone
and of each arm on the course of abstinence from street-opioids,
and took into account whether patients were switching from
buprenorphine to methadone at enrolment. Mixed models are
currently considered the most appropriate methods to use in
clinical trials with missing outcomes, as they meet intention-to-
treat criteria [20]. A log-rank test was used to compare Kaplan–
Meier curves for retention in treatment among patients who were
engaged in treatment, i.e. completed the induction phase (n = 188).
SAS (v.9.2) and STATA (v.12) statistical software packages were
used for the statistical analyses.
Results
Sites and physicians included in the study
Of 12 sites contacted in France, two refused to participate for
organizational reasons. The 10 participating sites each included a
SC and between 1 to 3 PC physicians in the nearby vicinity.
Among the 57 physicians (SC & PC) who agreed to participate, 32
(56%) enrolled at least one patient who met the inclusion criteria.
These 32 physicians were significantly different from the other 25
in that they were significantly older (p = 0.02) and had more years
of medical experience (p = 0.002).
Baseline data
The patients included were mainly men (84%), median [IQR]
age was 32 [27–38] years and 51% were switching from
buprenorphine. Table 2 reports the main patient characteristics
for each induction arm.
Patient disposition
From January 2009 to December 2010, the 32 physicians in the
10 trial sites enrolled 221 eligible individuals who were to be
followed up for 12 months. The flow of participants through each
stage is reported in Figure 1. All participants approached agreed
to participate in the trial before randomization. One pregnant
woman was excluded.
Among the 221 eligible patients, 66 and 155 were randomly
assigned to start methadone in SC and in PC, respectively.
However, 18 (27%) and 8 (5%) subsequently refused to be
inducted in SC and in PC (p,0.001), respectively. These 26
patients were classified as ‘‘failure’’ in the ITT analysis.
Of the 185 who started treatment, 5 SC and 2 PC patients
dropped out (discontinued study visits) during induction
(p = 0.026) (Figure 2) and were also classified as ‘‘failure’’ in the
ITT analysis. Ten SC and 16 PC patients discontinued follow-up
after induction (p = 0.13). They too were classified as ‘‘failure’’ in
the ITT analysis.
Overall, 15 (31%) of the 48 SC-inducted patients and 18 (12%)
of the 147 PC-inducted patients (p = 0.0023) discontinued follow-
up. Reasons for discontinuation are reported in Figure 1.
Finally, 33 SC-inducted and 129 PC-inducted patients were
present at M12 for the per protocol analysis. Data on the primary
outcome was missing for four of these individuals (2 in SC and 2 in
PC) who were therefore considered opioid users (i.e. ‘‘failure’’) in
the ITT and per protocol analyses.
Participants who were switching from buprenorphine were
older, more likely male, and, most importantly, had a higher
abstinence rate from street-opioids (38% vs. 12.5%) and cocaine
(78.5% vs. 68%) at baseline, than those who were out of opioid
maintenance treatment. However, as these differences were similar
Methadone Induction in Primary Care
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in both induction arms their compatibility in terms of the primary
outcome remains unaffected.
Among the 48 SC patients, 18 (14 before M3 and 4 others
before M6) changed to PC after induction, while one PC patient
changed to SC. Nine patients were re-inducted during the study
period after methadone interruption, two of these being re-
inducted twice.
Sixty percent of the participants were prescribed methadone
doses of between 60 and 80 mg between 11 and 17 days after
initiation.
HIV and HCV self-reported prevalence rates were 2% and
19%, respectively.
The end of the study was set for the 1st January 2012 to allow
one full year of follow-up for patients enrolled in December 2010.
Outcomes
Primary outcome was street opioid abstinence at 12 months and
secondary outcomes: abstinence during follow-up, engagement in
treatment, retention in treatment and satisfaction with the
explanations provided by the physician.
The rates of participants included in the study and still in
treatment at M12 were 129/155 = 83% for PC, 33/66 = 50% for
SC and 162/221 = 73% for total sample.
The ITT and per protocol analyses reporting the difference in
the proportions of street-opioid abstinent participants are
described in Table 3. In the former (n = 155 in PC, 66 in SC),
85/155 (55%) and 22/66 (33%) were classified as street-opioid
abstinent at M12 in PC and SC, respectively. The ITT analysis
demonstrated the non-inferiority of the PC arm: the difference
between the percentages of patients abstinent from street-opioids
between both arms at M12 and the 95% CI was 21.5 [7.7; 35.3] in
favor of PC. Although a per protocol analysis is not generally
considered suitable in a pragmatic trial [15], it was computed for
the sake of performing a comprehensive analysis. As expected, it
provided inconclusive results, as the difference between the
Figure 1. Flow chart of ANRS Methaville trial.
doi:10.1371/journal.pone.0112328.g001
Methadone Induction in Primary Care
PLOS ONE | www.plosone.org 5 November 2014 | Volume 9 | Issue 11 | e112328
proportions and the non-inferiority margins was 20.8 [218.8;
17.3], including the inferiority margin of 215.
Mixed models found no significant arm effect (p = 0.39) on
abstinence during follow-up, even when adjusting for the switch
from buprenorphine treatment. Abstinence from street-opioids
significantly increased between enrolment and M3 and remained
stable thereafter (Table 4). These results remained valid even after
adjusting for a possible heterogeneity effect among sites (i.e. study
sites with more than one PC physician versus sites with only one)
which was tested as a random effect factor in the mixed models but
which was not found to be statistically significant.
Engagement in treatment among those who were randomized
only concerned patients who completed the methadone induction
phase, i.e. 65% (43/66*100) for SC and 94% (145/155*100) for
PC, p,0.001 (Fig. 1)).
When we computed ‘‘retention in treatment’’ we only focused
on patients who had in fact started methadone treatment (i.e. 48 in
SC and 147 in PC). At M12, thirty-three (33/48*100 = 69%)
patients inducted in SC and 129 (129/147*100 = 88%) inducted in
PC were still in treatment.
The Kaplan-Meier curves in Fig. 2 show that retention in
methadone maintenance treatment was comparable between both
induction arms.
Interestingly, PC-inducted patients reported high satisfaction
with the explanations provided by their physician more often than
their SC-inducted counterparts (p = 0.01).
Prescribed methadone dose during the study
Regarding the median dose of prescribed methadone, there
were no significant differences between both arms. The median
[IQR] dose of methadone at M12 was 60 [45–90] mg in primary
care and 67.5 [50–82.5] mg in specialized care.
Table 2. Patient characteristics by induction arm (SC and PC) at baseline (ANRS Methaville trial).
SC (n=48) % or median [IQR] PC (n =147) (%) or median [IQR] Total % or median [IQR]
Gender 21 14 16
Male 79 86 84
Female 21 14 16
Age - years 30 [27–39] 32 [27–38] 32 [27–38]
Employment 44 53 51
High school certificate 43 32 35
Living in a couple 33 31 32
Children 33 39 38
Home owner or renter 56 64 62
Living area
Urban 59 52 54
Suburban 13 26 23
Rural 28 22 23
Switching from buprenorphine 52 51 51
Age at first drug use - years (n = 176) 18 [17–21] 18 [17–22] 18 [17–21]
Age at first regular drug use - years (n = 160) 20 [18–24] 20 [18–25] 20 [18–24]
History of drug injection (n = 175) 55 47 49
Age at first drug injection (n = 86) – years 22 [20–25] 21 [19–26] 22 [19–26]
Drug injection (n = 162)* 21 14 15
Drug snorting (n = 162)* 74 61 64
Use of street opioids (n = 187)* 79 69 72
Cocaine use (n = 162)* 26 27 27
Use of psychotropic drugs (n = 162)* 13 23 20
Daily cannabis use (n = 176)* 20 17 18
Hazardous alcohol consumption (n = 172)** 33 32 33
Depressive symptoms (n = 170)*** 32 41 39
History of suicide attempts (n = 157) 10 18 17
History of drug overdose (n = 188) 12 12 12
HIV+ (n = 152)**** 3 2 2
HCV+ (n = 140) **** 18 19 19
*during the previous 4 weeks.
**AUDIT score $7 for males and $6 for females.
***CES-D score.17 for males and.23 for females.
****among those who had already done a test.
doi:10.1371/journal.pone.0112328.t002
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Adverse events and self-reported symptoms
No overdose was observed during the induction phase but one
patient with a history of suicide attempts did intentionally overdose
during methadone maintenance. Apart from this case, no other
severe adverse events were reported during the trial.
The following symptoms were reported by more than 20% of
patients at month 3: fatigue/energy loss (49%), difficulty sleeping
(48%), constipation (40%), shortness of breath (33%), muscle pain
(32%), tingling (32%), poor appetite (31%), wheezing (31%), loss of
sexual desire (31%), stomach pain (28%), headaches (28%), joint
pain (23%), weight loss (20%) and blackouts (20%).
Discussion
This study is the first to randomize methadone initiation in
primary care. It was deliberately designed as a pragmatic trial
[21,22], i.e. having a real-life context to ensure external validity
and to provide information about methadone effectiveness,
irrespective of the induction site. It was also designed to provide
recommendations about the possible authorization of methadone
induction in primary care in France.
The main result of the trial is that induction in primary care is
feasible, as patients in primary care are not less likely to be
abstinent from street opioids compared with those inducted in
specialized care. Another interesting result is that PC appears to be
more attractive for opioid-dependent individuals, first because
patients randomized into primary care were more likely to accept
Figure 2. Retention in methadone maintenance treatment in patients (who completed the induction phase) in primary care (PC)
versus those who started in specialized care (SC).
doi:10.1371/journal.pone.0112328.g002
Table 3. ITT and per protocol analysis for the difference in the percentage of street-opioid abstinent patients by induction arm and
its 95% confidence interval.
Specialized care Primary care % [95% CI] of the difference
ITT analysis
Number of street-opioid abstinent patients at M12 22 85
Number of patients included 66 155
Street-opioid abstinent patients 33% 54% 21.5 [7.7; 35.3]
Per protocol analysis
Number of street-opioid abstinent patients at M12 22 85
Number of patients at M12 33 129
Street-opioid abstinent patients at M12 67% 66% 20.8 [218.8; 17.3]
doi:10.1371/journal.pone.0112328.t003
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treatment than those randomized in specialized centers. Secondly
patients who were inducted (after randomization) in primary care
were more likely to engage in treatment and report greater
satisfaction with medical information provided by their physician.
Furthermore, this study highlighted that once methadone treat-
ment was started, retention in treatment was similar in both arms.
These last two results reflect the two main criteria generally used
for assessing the effectiveness of treatments for opioid dependence
- namely retention and non-medical opioid use – and confirm the
comparable effectiveness of PC and SC over one year.
Similar results were found in a previous pragmatic trial
comparing maintenance in primary care and specialized care.
That trial also showed comparable outcomes and better satisfac-
tion with treatment in the primary care maintenance arm
[5,19,23].
Engagement in treatment was significantly lower in specialized
care than in primary care, with early discontinuation rates
significantly higher in the former group. This may be directly
attributable to the specific French context, where access to
buprenorphine already exists in primary care [4]. Indeed, previous
pragmatic trials for other treatments involving primary care [15]
have highlighted that strong patient engagement is related to the
high motivation of physicians enrolled in the trial. This was also
the case for physicians who accepted to participate in the present
trial. Indeed this is the population of physicians which will be
targeted if methadone induction becomes authorized in France.
In addition, it is important to note that the results of this trial by
and large are consistent with those found in previous literature
[24]. This shows that patients receiving methadone in primary
care have comparable treatment responses in terms of retention
and opioid use.
Using primary care as an entry point for opioid dependence
care (and also for associated comorbidities) has greatly contributed
to the scaling-up of treatment for opioid dependence in countries
such as the UK. Even more importantly it helps ‘‘normalize’’ care
for drug users. The availability of buprenorphine in primary care
has partially contributed to ‘‘normalize’’ care for drug users in
France as it means they can initiate a treatment option for opioid
dependence ‘‘free-of-charge’’ like any other patient, and do so in
structures which also provide care for other medical conditions to
the general population.
As the French public health authorities were particularly
concerned by the overdose risk during induction, the design of
the trial proposed a specific model of care for methadone
induction in PC in order to maximize safety. Individuals inducted
in PC were over-represented in order to better detect possible
overdoses during induction in the PC arm. As it happened, no
overdoses were observed during induction, confirming previous
results about the importance of a shared-care model to minimize
such a risk [16].
The strengths of this study lie in the following three key points:
first the identification of physicians who will likely be authorized to
induct methadone by public health authorities; second the choice
of a population of patients which was highly representative of
individuals seeking care for opioid dependence in France (non-
inclusion criteria were based exclusively on clinical practice
criteria to control the risk of overdose); third, the adoption of a
flexible treatment protocol where patients could choose to change
arm after induction reflecting current clinical practice in France.
One reason why equity of access to methadone and buprenor-
phine is important in France is because primary care physicians
regularly have to manage persistent buprenorphine-injection
practices and associated complications [25], which are often a
consequence of inadequate dosage prescription [26] or patient
dissatisfaction with treatment. For this reason it is important for
France to also consider patients who need to switch from
buprenorphine to methadone for medical reasons. Despite the
wide availability of generic buprenorphine in France, switching
from buprenorphine to methadone in primary care could result in
reduced costs for care of opioid dependence. However, methadone
is likely to present more drug-drug interactions than buprenor-
phine for those on HIV or HCV medication. Consequently, before
starting methadone in patients already receiving such medication,
physicians should know how to modify methadone doses
accordingly. This is why primary care physicians involved in the
present trial received training and appropriate guidelines for all
possible drug-drug interactions with methadone treatment,
together with guidance about the differences between starting
methadone in buprenorphine patients compared with methadone
induction in street-opioid users.
A substantial portion of the participants starting methadone in
SC switched from buprenorphine to methadone. This is the usual
treatment chain for opioid-dependent patients in France. This is
not so frequent in other countries. However, switching in France is
impossible in areas underserved by specialized centers for
substance dependence (i.e. non-urban areas) where general
methadone initiation is not available.
Although methadone induction is already possible in primary
care in some countries including the UK and Switzerland, no
previous trial has compared methadone outcomes over one year as
a function of the site of induction. The randomization of a specific
Table 4. Odds ratio from the adjusted mixed model for abstinence from opioids use during the treatment (n = 615 visits and 188
patients).
OR (IC95%)
Time since methadone treatment initiation
M3 vs. M0 19.62 (8.69–44.33)
M6 vs. M0 16.73 (7.73–36.19)
M12 vs. M0 19.42 (8.98–41.98)
Arm induction
PC vs. SC 1.58 (0.57–4.37)
switching from buprenorphine
Yes vs. No 1.99 (0.85–4.67)
doi:10.1371/journal.pone.0112328.t004
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model of care for drug users has already been performed in other
trials [5,27,28] which had similar public health objectives.
The population targeted in this trial is representative of those
seeking care for opioid dependence in France [29] and in other
countries where similar models of specialized care are available
[30–33]. However it is difficult to say to what extent these results
remain valid in countries where access to opioid maintenance
treatment is not free for drug users. Nevertheless, the study was
performed according to standard international guidelines [34,35]
in order to make our results as relevant as possible for other
contexts.
Among the limitations of the trial, the need for physical
proximity between the primary care physician and specialized
centers obliged us to target areas where patients’ need for
methadone was already being substantially met by the specialized
centers rather than underserved areas. This resulted in slowed
enrolment rates and the enforced extension of the duration of
enrolment period. Certainly a larger sample size and longer
follow-up would have provided long term comparisons and
increased the study’s power, but this was not feasible both because
of the practical reasons outlined above and cost reasons. The
possible effect of heterogeneity between sites (i.e. sites with more
than one PC physician versus sites having only one) was tested as a
random effect factor in mixed models but was not found to be
significant. It is possible that a larger sample size could have
altered these results. However, it was important to represent
different site sizes (i.e. those with different numbers of participating
PC physicians) in the trial for external validity reasons.
Today, many governments of countries with HCV and HIV
epidemics driven by drug use are still reluctant to introduce or
scale up methadone treatment using alternative models of care,
even though such an approach would be cost-effective, especially
for controlling HIV and HCV [36].
The model used for primary care in this study may be of interest
in other settings where access to methadone is needed for HIV and
HCV prevention purposes. However, it is important to remember
that our results strongly depend on the specific context of France
where primary care already plays an important role in engaging
patients in treatment for opioid dependence.
In conclusion, methadone induction in primary care is feasible
and acceptable for both physicians and patients. It is as effective as
induction in specialized care in reducing street-opioid use and
ensuring engagement and retention in treatment for opioid
dependence.
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